Search

Your search keyword '"Sunada, Masumi"' showing total 3 results
Start Over Author "Sunada, Masumi" Publisher elsevier bv
3 results on '"Sunada, Masumi"'

1. Nivolumab for malignant transformation of ovarian mature cystic teratoma

Author

Yoshimura, Kayoko, primary, Yamanoi, Koji, additional, Kanai, Masashi, additional, Okunomiya, Asuka, additional, Sagae, Yusuke, additional, Sunada, Masumi, additional, Taki, Mana, additional, Ukita, Masayo, additional, Chigusa, Yoshitsugu, additional, Horie, Akihito, additional, Yamaguchi, Ken, additional, Hamanishi, Junzo, additional, Minamiguchi, Sachiko, additional, Yamamoto, Noboru, additional, Muto, Manabu, additional, and Mandai, Masaki, additional

Published
2022
Full Text
View/download PDF

2. Nivolumab for malignant transformation of ovarian mature cystic teratoma

Author

70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, 80378736, 00335283, 40360698, Yoshimura, Kayoko, Yamanoi, Koji, Kanai, Masashi, Okunomiya, Asuka, Sagae, Yusuke, Sunada, Masumi, Taki, Mana, Ukita, Masayo, Chigusa, Yoshitsugu, Horie, Akihito, Yamaguchi, Ken, Hamanishi, Junzo, Minamiguchi, Sachiko, Yamamoto, Noboru, Muto, Manabu, Mandai, Masaki, 70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, 80378736, 00335283, 40360698, Yoshimura, Kayoko, Yamanoi, Koji, Kanai, Masashi, Okunomiya, Asuka, Sagae, Yusuke, Sunada, Masumi, Taki, Mana, Ukita, Masayo, Chigusa, Yoshitsugu, Horie, Akihito, Yamaguchi, Ken, Hamanishi, Junzo, Minamiguchi, Sachiko, Yamamoto, Noboru, Muto, Manabu, and Mandai, Masaki

Abstract

Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid tumor recurrence occurred during postoperative chemotherapy (paclitaxel + ifosfamide + cisplatin). The results of comprehensive genomic profiling test performed early in the postoperative period showed a high tumor mutational burden of 23 mutations/Mb. Treatment with nivolumab monotherapy has promptly been initiated and has been very successful for more than one year.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results